Analysis of Haemophilus influenzae type B conjugate and diphtheria- tetanus-pertussis combination vaccines

Journal of Infectious Diseases

Volumn 174, Issue SUPPL. 3, 1996, Pages

  Eskola, Juhani ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; COMBINATION CHEMOTHERAPY; DIPHTHERIA; DRUG CONJUGATION; FINLAND; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INFANT; INFLUENZA VACCINATION; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; REVIEW; TETANUS; VACCINATION;

EID: 0029858878     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.supplement_3.s302     Document Type: Review

References (18)

1. Chen RT. Surveillance of the safety of simultaneous administration of vaccines: the CDC experience. Presented at the International Workshop on Combined Vaccines and Simultaneous Administration: Current Issues and Perspectives, Bethesda, Maryland, 28-30 July 1993.
2. Eskola J, Kāyhty H, Gordon LK, et al. Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-tetanus-pertussis and inactivated poliovirus vaccinations of childhood. Pediatr Infect Dis J 1988; 7:480-4.
3. Ferreccio C, Clemens J, Avendano A, et al. The clinical and immunologic response of Chilean infants to Haemophilus influence type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with diphtheria-tetanus toxoid-pertussis vaccine at 2, 4 and 6 months of age. Pediatr Infect Dis J 1991; 10:764-71.
4. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus type b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis J 1991; 10:758-61.
5. Clemens JD, Ferreccio C, Levine MM, et al. Impact of Haemophilus influenzas type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 1992;267:673-8.
6. Scheifele D, Bjornson G, Barreto L, et al. Controlled trial of Haemophilus influenzas type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection. Vaccine 1992; 10:455-60.
7. Scheifele D, Barreto L, Meekison W, et al. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? Can Med Assoc J 1993; 149:1105-12.
8. Mulholland EK, Ahonkhai VI, Greenwood AM, et al. Safety and immunogenicity of Haemophilus influenzae type B-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. Pediatr Infect Dis J 1993; 12:632-7.
9. Paradiso PR, Hogerman DA, Madore DV, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 1993;92:827-32.
10. Avendano A, Ferreccio C, Lagos R, et al. Haemophilus influenzas type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1993; 12:638-43.
11. Kaplan SL, Lauer BA, Ward MA, et al. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J Pediatr 1994;124:323-7.
12. Gold R, Scheifele D, Barreto L, et al. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J 1994; 13:348-55.
13. Dagan R, Botujansky C, Watemberg N, et al. Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr Infect Dis J 1994; 13:356-61.
14. FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children. MMWR Morb Mortal Wkly Rep 1993; 42:296-8.
15. Food and Drug Administration approval of use of Haemophilus influenzae type b conjugate vaccine reconstituted with diphtheria-tetanus-pertussis vaccine for infants and children. MMWR Morb Mortal Wkly Rep 1993; 42:964-5.
16. Shinefield H, Black S. Conjugate Hib vaccines and their combinations: present success and future possibilities. JAMA 1993; SEA edition: 20-3.
17. Clemens JD, Brenner R, Rao M. Interactions between PRP-T vaccine against Haemophilus influenzae type b and conventional infant vaccines. Lessons for future studies of simultaneous immunization and combination vaccines. Ann NY Acad Sci 1995;754:255-66.
18. Kovel A, Wald ER, Guerra N, et al. Safety and immunogenicity of acellular diphtheria-tetanus-pertussis and Haemophilus conjugate vaccines given in combination or at separate injection sites. J Pediatr 1992; 120:84-7.